Philippe Muller

This inventor holds 17 USPTO granted patents and 1 published patent application, plus 8 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Janssen Pharmaceutica Nv, Janssen Sciences Ireland Uc, Tibotec Pharmaceuticals Ltd.. Active years: 2000-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philippe Muller. Retrieved from https://idiyas.com/inventor/philippe-muller

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 1)

% Patents Active = 82.4

CIPO Patents = 8 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 4)

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 177(Granted Patents)

Location History:

And{acute over (e)}, FR (2001)
Ande, FR (2000 - 2019)
Andé, FR (2002 - 2023)

Company Filing History:

6 out of 2,101

Janssen Pharmaceutica Nv

patents

5 out of 111

Janssen Sciences Ireland Uc

patents

4 out of 67

Tibotec Pharmaceuticals Ltd.

patents

4. 2 out of 64

Janssen Sciences Ireland Unlimited Company

patents

Years Active: 2000-2023

Loading Chart...

Areas of Expertise:

Macrocyclic Deaza-Purinones

Purine Derivatives

Pyrimidine Derivatives

Benzimidazole Inhibitors

Viral Infections

Bacterial Diseases

Farnesyl Protein Transferase

Morpholinyl Compounds

Heterocyclic Amines

Respiratory Syncytial Virus

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11702426 - Macrocyclic deaza-purinones for the treatment of viral infections (2023-07-18),

2. 10829494 - Macrocyclic deaza-purinones for the treatment of viral infections (2020-11-10),

3. 10280180 - Macrocyclic purines for the treatment of viral infections (2019-05-07),

4. 10280167 - Purine derivatives for the treatment of viral infections (2019-05-07),

5. 10266543 - Macrocyclic deaza-purinones for the treatment of viral infections (2019-04-23),

6. 10221157 - Pyrimidine derivatives for the treatment of bacterial diseases (2019-03-05),

7. 9725432 - Pyrimidine derivatives for the treatment of bacterial diseases (2017-08-08),

8. 9556176 - Purine derivatives for the treatment of viral infections (2017-01-31),

9. 8883837 - Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication (2014-11-11),

10. 8278455 - 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication (2012-10-02),

11. 8178694 - Heterocyclylaminoalkyl substituted benzimidazoles (2012-05-15),

12. 8044073 - Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication (2011-10-25),

13. 8034835 - 1-[[2-amino-3-(substituted alkyl)-3H-benzimidazolyl[methyl]-3-substituted-1,3-dihydro-benzoimidazol-2-ones and structural analogs (2011-10-11),

14. 7449463 - Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication (2008-11-11),

15. 6420387 - Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives (2002-07-16),

Title: Discovering the Innovations of Philippe Muller

Introduction

Philippe Muller, an innovative inventor based in Andé, France, has made significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 17 patents, he has focused his efforts on developing novel compounds and solutions that address critical health challenges, particularly in the area of viral infections.

Latest Patents

Among his latest innovations are the macrocyclic deaza-purinones, which are derivatives designed for the treatment of viral infections. This invention encompasses processes for their preparation, pharmaceutical compositions, and their practical applications in treating various viral diseases. The dual focus on drug development and therapeutic application highlights Muller's commitment to advancing medical science.

Career Highlights

Throughout his distinguished career, Philippe Muller has worked with esteemed organizations, including Janssen Pharmaceutica NV and Janssen Sciences Ireland UC. His experience in these leading pharmaceutical companies has solidified his reputation as a prominent inventor in the industry, enabling him to contribute greatly to the development of innovative therapeutic solutions.

Collaborations

Muller has collaborated with several notable professionals in his field, including Frédéric Marc Maurice Doublet and Jean-François Bonfanti. These partnerships have fostered an environment of creativity and innovation, allowing for the exchange of ideas that drive forward-thinking research and development in pharmacology.

Conclusion

Philippe Muller's body of work exemplifies the impact that passionate inventors can have in the realm of medical advancements. His innovative approach to creating effective treatments for viral infections through macrocyclic deaza-purinones is a testament to his dedication to improving healthcare outcomes. As he continues to push the boundaries of science, his journey serves as an inspiration for aspiring inventors and innovators around the world.

Profile summary based on public USPTO records.